Business Wire

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Business Wire

Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting

PARIS--(BUSINESS WIRE)--Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the ...
EurekAlert!

New antibody selectively targets immune cells that suppress anti-tumor responses

“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME” “Taken ...
BioWorld

NEO-TRA1, a novel non-α agonist of the IL-2 receptor that selectively expands Treg populations

Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
Nasdaq

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical ...

Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further ...